Figure 2
Perfusion and ADC lesion volume in treatment vs. control group. (A) MRI perfusion maps CBV, CBF, TTP and MTT did not show a significant difference in decreased perfusion volume between control and treatment group before treatment (CBV: 11.0 [10.3 to 12.4] vs. 6.9 [3.1 to 18.9] mm3, P = 0.69, CBF: 13.9 [12.3 to 14.9] vs. 12.3 [6.3 to 18.9] mm3, P = 0.69, TTP: 13.0 [12.2 to 15.9] vs. 14.2 [10.5 to 18.9] mm3, P = 0,73 and MTT: 12.3 [11.8 to 14.5] vs. 11.7 [8.8 to 23.4] mm3, P = 0.69). (B) ADC lesion volume had a median volume of 63.5 [21.4 to 79.8] mm3 in the control group and 97.2 [37.8 to 106.9] mm3 in the treatment group before treatment (P = 0.15). 24 hours after treatment ADC had a lesion volumes of 45.1 mm3 [20.2 to 89.5] in the tacrolimus group compared to 82.0 mm3 [11.7 to 72.6] in the control group, P = 0.15 (Both graph show median, ns: P = not significant, n = 5 for both groups).
